Genomics and the Immune Landscape of Osteosarcoma

被引:47
作者
Wu, Chia-Chin [1 ]
Livingston, J. Andrew [2 ,3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA
来源
CURRENT ADVANCES IN THE SCIENCE OF OSTEOSARCOMA: RESEARCH PERSPECTIVES: TUMOR BIOLOGY, ORGAN MICROENVIRONMENT, POTENTIAL NEW THERAPEUTIC TARGETS, AND CANINE MODELS, 2ND EDITION | 2020年 / 1258卷
关键词
Osteosarcoma; Genomics; Next-generationsequencing (NGS); Chromothripsis; Telomere lengthening; Immune profiling; CHROMOSOMAL INSTABILITY; PD-L1; EXPRESSION; TP53; MUTATIONS; HUMAN CANCERS; DNA-DAMAGE; P53; LOSS; CELLS; TELOMERES; REPAIR; CHROMOTHRIPSIS;
D O I
10.1007/978-3-030-43085-6_2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Conventional osteosarcoma (OS) is a high-grade intraosseous malignancy with production of osteoid matrix; however, a deeper dive into the underlying genetics reveals genomic complexity and instability that result in significant tumor heterogeneity. While early karyotyping studies demonstrated aneuploidy with chromosomal complexity and structural rearrangements, further investigations have identified few recurrent genetic alterations with the exception of the tumor suppressors TP53 and RB1. More recent studies utilizing next-generation sequencing (NGS; whole-exome sequencing, WES; and whole-genome sequencing, WGS) reveal a genomic landscape predominantly characterized by somatic copy number alterations rather than point/indel mutations. Despite its genomic complexity, OS has shown variable immune infiltrate and limited immunogenicity. In the current chapter, we review the hallmarks of OS genomics across recent NGS studies and the immune profile of OS including a large institutional cohort of OS patients with recurrent and metastatic disease. Understanding the genomic and immune landscape of OS may provide opportunities for translation in both molecularly targeted therapies and novel immuno-oncology approaches.
引用
收藏
页码:21 / 36
页数:16
相关论文
共 80 条
[71]   Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape [J].
Wellenstein, Max D. ;
de Visser, Karin E. .
IMMUNITY, 2018, 48 (03) :399-416
[72]   Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways [J].
Werner, Haim ;
Sarfstein, Rive ;
LeRoith, Derek ;
Bruchim, Ilan .
FRONTIERS IN ONCOLOGY, 2016, 6
[73]   Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial [J].
Wilky, Breelyn A. ;
Trucco, Matte M. ;
Subhawong, Ty K. ;
Florou, Vaia ;
Park, Wungki ;
Kwon, Deukwoo ;
Wieder, Eric D. ;
Kolonias, Despina ;
Rosenberg, Andrew E. ;
Kerr, Darcy A. ;
Sfakianaki, E. Rosyni ;
Foley, Mark ;
Merchan, Jaime R. ;
Komanduri, Krishna, V ;
Trent, Jonathan C. .
LANCET ONCOLOGY, 2019, 20 (06) :837-848
[74]  
Wu CC, 2019, NAT COMMUN, V11
[75]   TP53 mutations and outcome in osteosarcoma:: A prospective, multicenter study [J].
Wunder, JS ;
Gokgoz, N ;
Parkes, R ;
Bull, SB ;
Eskandarian, S ;
Davis, AM ;
Beauchamp, CP ;
Conrad, EU ;
Grimer, RJ ;
Healey, JH ;
Malkin, D ;
Mangham, DC ;
Rock, MJ ;
Bell, RS ;
Andrulis, IL .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1483-1490
[76]   Circulating levels of IGF-1 directly regulate bone growth and density [J].
Yakar, S ;
Rosen, CJ ;
Beamer, WG ;
Ackert-Bicknell, CL ;
Wu, YP ;
Liu, JL ;
Ooi, GT ;
Setser, J ;
Frystyk, J ;
Boisclair, YR ;
LeRoith, D .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (06) :771-781
[77]  
Yang Y, 2016, ONCOTARGET, V7
[78]   We of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage [J].
Yoshida, K ;
Miki, Y .
CANCER SCIENCE, 2004, 95 (11) :866-871
[79]   Inferring tumour purity and stromal and immune cell admixture from expression data [J].
Yoshihara, Kosuke ;
Shahmoradgoli, Maria ;
Martinez, Emmanuel ;
Vegesna, Rahulsimham ;
Kim, Hoon ;
Torres-Garcia, Wandaliz ;
Trevino, Victor ;
Shen, Hui ;
Laird, Peter W. ;
Levine, Douglas A. ;
Carter, Scott L. ;
Getz, Gad ;
Stemke-Hale, Katherine ;
Mills, Gordon B. ;
Verhaak, Roel G. W. .
NATURE COMMUNICATIONS, 2013, 4
[80]  
Zhao X, 2017, PHARM THER, V181, P76